Cost of Illness of Spinal Muscular Atrophy (SMA) in Italy

Global and Regional Health Technology Assessment - Italy
doi 10.1177/2284240319867662
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Aboutscience Srl

Related search

Psy71 - Economic Burden of Spinal Muscular Atrophy in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost of Illness Analysis of Duchenne Muscular Dystrophy in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Autonomic Dysfunction in Spinal Muscular Atrophy

Turkiye Klinikleri Pediatri
Child HealthPediatricsPerinatology
2019English

Spinal Muscular Atrophy Type 1

Pediatric Critical Care Medicine
Child HealthCritical CarePediatricsPerinatologyIntensive Care Medicine
2012English

014 AVXS-101 Gene-Replacement Therapy (GRT) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs

Frontiers in Neurology
Neurology
2020English

P.065 AVXS-101 Gene-Replacement Therapy (GRT)) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Canadian Journal of Neurological Sciences
MedicineNeurology
2019English

Genotipe-Phenotipe Correlation in Spinal Muscle Atrophy (SMA)

Materia Medica
2015English

Carrier Screening for Spinal Muscular Atrophy

Genetics in Medicine
MedicineGenetics
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy